1. Home
  2. STRO

STRO

Sutro Biopharma Inc.

Logo Sutro Biopharma Inc.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-23-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Founded: N/A Country:
N/A
Employees: N/A City: SOUTH SAN FRANCISCO
Market Cap: 290.0M IPO Year: 2018
Target Price: $13.14 AVG Volume (30 days): 998.5K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.78 EPS Growth: N/A
52 Week Low/High: $2.01 - $6.13 Next Earning Date: 01-01-0001
Revenue: $153,731,000 Revenue Growth: 126.84%
Revenue Growth (this year): -63.47% Revenue Growth (next year): 33.58%

Share on Social Networks: